ConductScience.org, home
A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa
API referenceFor AI assistants

Trial · NCT03060629

Adverse events166

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 166

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
otherGenitourinary chlamydia infectionInfections and infestationsGroup 1: Ad26.Mos.HIV Vaccine5281,317
otherGenitourinary chlamydia infectionInfections and infestationsGroup 2: Placebo5271,319
otherGenitourinary tract gonococcal infectionInfections and infestationsGroup 1: Ad26.Mos.HIV Vaccine2691,317
otherGenitourinary tract gonococcal infectionInfections and infestationsGroup 2: Placebo2881,319
otherSyphilisInfections and infestationsGroup 1: Ad26.Mos.HIV Vaccine691,317
otherSyphilisInfections and infestationsGroup 2: Placebo791,319
otherUpper respiratory tract infectionInfections and infestationsGroup 1: Ad26.Mos.HIV Vaccine791,317
otherUpper respiratory tract infectionInfections and infestationsGroup 2: Placebo771,319
otherVulvovaginitis trichomonalInfections and infestationsGroup 1: Ad26.Mos.HIV Vaccine2451,317
otherVulvovaginitis trichomonalInfections and infestationsGroup 2: Placebo2391,319
otherVaginal dischargeReproductive system and breast disordersGroup 1: Ad26.Mos.HIV Vaccine1021,317
otherVaginal dischargeReproductive system and breast disordersGroup 2: Placebo1131,319
seriousAnaemiaBlood and lymphatic system disordersGroup 1: Ad26.Mos.HIV Vaccine11,317
seriousAnaemiaBlood and lymphatic system disordersGroup 2: Placebo01,319
seriousCongenital anomaly in offspringCongenital, familial and genetic disordersGroup 1: Ad26.Mos.HIV Vaccine21,317
seriousCongenital anomaly in offspringCongenital, familial and genetic disordersGroup 2: Placebo21,319
seriousAbdominal massGastrointestinal disordersGroup 1: Ad26.Mos.HIV Vaccine11,317
seriousAbdominal massGastrointestinal disordersGroup 2: Placebo01,319
seriousAbdominal painGastrointestinal disordersGroup 1: Ad26.Mos.HIV Vaccine11,317
seriousAbdominal painGastrointestinal disordersGroup 2: Placebo01,319

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03060629/events

API referenceFor AI assistants